1. The majority of treatment-related adverse events were mild-to-moderate gastrointestinal events with no reported deaths. 2. Amycretin resulted in significant weight loss across most doses compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Amycretin is a novel therapy that activates GLP-1 and amylin receptors, two hormones involved in regulating appetite and metabolism. Until […]